Literature DB >> 22116008

Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders.

Matthew E Hirschtritt1, Maria E Pagano, Kelly M Christian, Nora K McNamara, Robert J Stansbrey, Jacqui Lingler, Jon E Faber, Christine A Demeter, Denise Bedoya, Robert L Findling.   

Abstract

Our recent 8-week, randomized, placebo-controlled trial of fluoxetine in adolescents (ages 12-17 years) with comorbid depression and substance use disorder (SUD) did not detect a significant antidepressant treatment effect. The purpose of this secondary analysis was to explore moderators of the effect of fluoxetine in this sample. Static moderators measured at baseline were depression chronicity and hopelessness severity; time-varying moderators measured at baseline and weekly during the 8-week trial period were alcohol and marijuana use severity. Treatment effects on depression outcomes were examined among moderating subgroups in random effects regression models. Subjects assigned to fluoxetine treatment with chronic depression at baseline (p = .04) or no more than moderate alcohol use during the trial (p = .04) showed significantly greater decline in depression symptoms in comparison to placebo-assigned subgroups. The current analysis suggests that youth with chronic depression and no more than moderate alcohol consumption are likely to respond better to treatment with fluoxetine compared with placebo than youth with transient depression and heavy alcohol use.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116008      PMCID: PMC3415216          DOI: 10.1016/j.jsat.2011.09.010

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  32 in total

Review 1.  Mediators and moderators of treatment effects in randomized clinical trials.

Authors:  Helena Chmura Kraemer; G Terence Wilson; Christopher G Fairburn; W Stewart Agras
Journal:  Arch Gen Psychiatry       Date:  2002-10

2.  Psychiatric disorders and attempted suicide among adolescents with substance use disorders.

Authors:  Thomas M Kelly; Jack R Cornelius; Duncan B Clark
Journal:  Drug Alcohol Depend       Date:  2004-01-07       Impact factor: 4.492

3.  A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders.

Authors:  Paula D Riggs; Susan K Mikulich-Gilbertson; Robert D Davies; Michelle Lohman; Constance Klein; Shannon K Stover
Journal:  Arch Pediatr Adolesc Med       Date:  2007-11

Review 4.  Antidepressant drug effects and depression severity: a patient-level meta-analysis.

Authors:  Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett
Journal:  JAMA       Date:  2010-01-06       Impact factor: 56.272

5.  Axis I comorbidity in adolescent inpatients referred for treatment of substance use disorders.

Authors:  Tobias Langenbach; Alexandra Spönlein; Eva Overfeld; Gaby Wiltfang; Niklas Quecke; Norbert Scherbaum; Peter Melchers; Johannes Hebebrand
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2010-09-28       Impact factor: 3.033

Review 6.  Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.

Authors:  Edward V Nunes; Frances R Levin
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

Review 7.  Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder.

Authors:  Jeffrey A Bridge; Boris Birmaher; Satish Iyengar; Rémy P Barbe; David A Brent
Journal:  Am J Psychiatry       Date:  2008-12-01       Impact factor: 18.112

8.  Suicide attempts among depressed adolescents in primary care.

Authors:  Samantha R Fordwood; Joan R Asarnow; Diana P Huizar; Steven P Reise
Journal:  J Clin Child Adolesc Psychol       Date:  2007 Jul-Sep

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Depression in substance-dependent delinquents.

Authors:  P D Riggs; S Baker; S K Mikulich; S E Young; T J Crowley
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1995-06       Impact factor: 8.829

View more
  6 in total

1.  Do improvements in substance use and mental health symptoms during treatment translate to long-term outcomes in the opposite domain?

Authors:  Rajeev Ramchand; Beth Ann Griffin; Mary Ellen Slaughter; Daniel Almirall; Daniel F McCaffrey
Journal:  J Subst Abuse Treat       Date:  2014-07-12

Review 2.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.

Authors:  Glenda M MacQueen; Benicio N Frey; Zahinoor Ismail; Natalia Jaworska; Meir Steiner; Ryan J Van Lieshout; Sidney H Kennedy; Raymond W Lam; Roumen V Milev; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 3.  Treating Mental Health and Substance Use Disorders in Adolescents: What Is on the Menu?

Authors:  Stanley Brewer; Mark D Godley; Leslie A Hulvershorn
Journal:  Curr Psychiatry Rep       Date:  2017-01       Impact factor: 5.285

Review 4.  Pharmacotherapies for cannabis dependence.

Authors:  Kushani Marshall; Linda Gowing; Robert Ali; Bernard Le Foll
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

5.  SMAD4 regulates cell motility through transcription of N-cadherin in human pancreatic ductal epithelium.

Authors:  Ya'an Kang; Jianhua Ling; Rei Suzuki; David Roife; Xavier Chopin-Laly; Mark J Truty; Deyali Chatterjee; Huamin Wang; Ryan M Thomas; Matthew H Katz; Paul J Chiao; Jason B Fleming
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

6.  Pharmacotherapies for cannabis dependence.

Authors:  Suzanne Nielsen; Linda Gowing; Pamela Sabioni; Bernard Le Foll
Journal:  Cochrane Database Syst Rev       Date:  2019-01-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.